| Jeffrey A Sather, MD | |
|
2305 37th Ave Sw, Minot, ND 58701-7669 | |
| (701) 857-5000 | |
| Not Available |
| Full Name | Jeffrey A Sather |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 26 Years |
| Location | 2305 37th Ave Sw, Minot, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508937657 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 8688 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Trinity Hospitals | Minot, ND | Hospital |
| Trinity Kenmare Community Hospital | Kenmare, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trinity Health | 7911816020 | 287 |
| Trinity Kenmare Hospital | 9931018777 | 10 |
News Archive
Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.
Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.
Hanger Orthopedic Group, Inc. announced today the pricing of the previously announced public offering of 2,000,000 shares of its common stock by Ares Corporate Opportunities Fund, L.P. at a public offering price of $20.00 per share. The transaction is expected to close on December 15, 2010. The shares sold were a portion of the currently outstanding shares issued to Ares in August 2008 in connection with the conversion of all of Hanger's Series A Convertible Preferred Stock into common stock.
Adolescents require 8-10 hours of sleep at night for optimal health, according to sleep experts, yet more than 70 percent of high school students get less than that.
Health Net of Arizona is joining with Banner Health to offer a new type of HMO plan. In other news, Health News Florida reports on WellCare and Humana's profits.
› Verified 6 days ago
| Entity Name | Trinity Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083653752 PECOS PAC ID: 7911816020 Enrollment ID: O20031106000316 |
News Archive
Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.
Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.
Hanger Orthopedic Group, Inc. announced today the pricing of the previously announced public offering of 2,000,000 shares of its common stock by Ares Corporate Opportunities Fund, L.P. at a public offering price of $20.00 per share. The transaction is expected to close on December 15, 2010. The shares sold were a portion of the currently outstanding shares issued to Ares in August 2008 in connection with the conversion of all of Hanger's Series A Convertible Preferred Stock into common stock.
Adolescents require 8-10 hours of sleep at night for optimal health, according to sleep experts, yet more than 70 percent of high school students get less than that.
Health Net of Arizona is joining with Banner Health to offer a new type of HMO plan. In other news, Health News Florida reports on WellCare and Humana's profits.
› Verified 6 days ago
| Entity Name | Good Samaritan Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588751325 PECOS PAC ID: 6002716701 Enrollment ID: O20040225000266 |
News Archive
Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.
Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.
Hanger Orthopedic Group, Inc. announced today the pricing of the previously announced public offering of 2,000,000 shares of its common stock by Ares Corporate Opportunities Fund, L.P. at a public offering price of $20.00 per share. The transaction is expected to close on December 15, 2010. The shares sold were a portion of the currently outstanding shares issued to Ares in August 2008 in connection with the conversion of all of Hanger's Series A Convertible Preferred Stock into common stock.
Adolescents require 8-10 hours of sleep at night for optimal health, according to sleep experts, yet more than 70 percent of high school students get less than that.
Health Net of Arizona is joining with Banner Health to offer a new type of HMO plan. In other news, Health News Florida reports on WellCare and Humana's profits.
› Verified 6 days ago
| Entity Name | Trinity Kenmare Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226671 PECOS PAC ID: 9931018777 Enrollment ID: O20040702000319 |
News Archive
Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.
Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.
Hanger Orthopedic Group, Inc. announced today the pricing of the previously announced public offering of 2,000,000 shares of its common stock by Ares Corporate Opportunities Fund, L.P. at a public offering price of $20.00 per share. The transaction is expected to close on December 15, 2010. The shares sold were a portion of the currently outstanding shares issued to Ares in August 2008 in connection with the conversion of all of Hanger's Series A Convertible Preferred Stock into common stock.
Adolescents require 8-10 hours of sleep at night for optimal health, according to sleep experts, yet more than 70 percent of high school students get less than that.
Health Net of Arizona is joining with Banner Health to offer a new type of HMO plan. In other news, Health News Florida reports on WellCare and Humana's profits.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey A Sather, MD Po Box 5010, Minot, ND 58702-5010 Ph: (701) 418-8000 | Jeffrey A Sather, MD 2305 37th Ave Sw, Minot, ND 58701-7669 Ph: (701) 857-5000 |
News Archive
Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.
Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.
Hanger Orthopedic Group, Inc. announced today the pricing of the previously announced public offering of 2,000,000 shares of its common stock by Ares Corporate Opportunities Fund, L.P. at a public offering price of $20.00 per share. The transaction is expected to close on December 15, 2010. The shares sold were a portion of the currently outstanding shares issued to Ares in August 2008 in connection with the conversion of all of Hanger's Series A Convertible Preferred Stock into common stock.
Adolescents require 8-10 hours of sleep at night for optimal health, according to sleep experts, yet more than 70 percent of high school students get less than that.
Health Net of Arizona is joining with Banner Health to offer a new type of HMO plan. In other news, Health News Florida reports on WellCare and Humana's profits.
› Verified 6 days ago
Lovita Scrimshaw, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2305 37th Ave Sw, Minot, ND 58701 Phone: 701-857-5000 | |
Dr. Justin Alexander Walters, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: #1 Burdick Expy W, Minot, ND 58701 Phone: 701-857-5260 Fax: 701-857-3260 | |
Dr. Kevin Franks, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2305 37th Ave Sw, Minot, ND 58701 Phone: 701-857-5000 | |
Thomas L Walsh, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: #1 Burdick Expy. W., Minot, ND 58701 Phone: 701-857-5260 Fax: 701-857-3260 | |
Susan F Gokey, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Burdick Expy W, Minot, ND 58701 Phone: 701-857-5260 Fax: 701-857-3260 | |
Joan Ugochukwu Agwai, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2305 37th Ave Sw, Minot, ND 58701 Phone: 701-857-5000 | |
Karina Walker Weathers, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Burdick Expy W, Minot, ND 58701 Phone: 701-857-5260 Fax: 701-857-3260 |